Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Free Cash Flow: 2013-2025

Historic Free Cash Flow for Fortress Biotech (FBIO) over the last 13 years, with Sep 2025 value amounting to -$6.1 million.

  • Fortress Biotech's Free Cash Flow rose 67.26% to -$6.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$66.1 million, marking a year-over-year increase of 35.31%. This contributed to the annual value of -$80.2 million for FY2024, which is 37.49% up from last year.
  • As of Q3 2025, Fortress Biotech's Free Cash Flow stood at -$6.1 million, which was up 77.83% from -$27.6 million recorded in Q2 2025.
  • In the past 5 years, Fortress Biotech's Free Cash Flow ranged from a high of -$6.1 million in Q3 2025 and a low of -$48.2 million during Q1 2022.
  • Moreover, its 3-year median value for Free Cash Flow was -$23.2 million (2024), whereas its average is -$23.8 million.
  • Per our database at Business Quant, Fortress Biotech's Free Cash Flow slumped by 116.78% in 2022 and then soared by 67.26% in 2025.
  • Quarterly analysis of 5 years shows Fortress Biotech's Free Cash Flow stood at -$40.7 million in 2021, then decreased by 17.91% to -$47.9 million in 2022, then grew by 27.06% to -$35.0 million in 2023, then soared by 63.08% to -$12.9 million in 2024, then skyrocketed by 67.26% to -$6.1 million in 2025.
  • Its last three reported values are -$6.1 million in Q3 2025, -$27.6 million for Q2 2025, and -$19.6 million during Q1 2025.